IBRX vs MRK
IBRX: ImmunityBio develops innovative immunotherapies and cell-based cancer vaccines that leverage its Cancer BioShield platform to treat oncology and infectious disease patients. MRK: Merck & Co. is a leading global biopharmaceutical firm dedicated to delivering life-saving vaccines and innovative therapeutic medicines for major disease areas.
Side-by-side fundamentals
| Metric | IBRX | MRK | Edge |
|---|---|---|---|
| Price as of 2026-08-11 close | $7.60 | $130.42 | |
| Market cap as of 2026-08-12 | $8.1B | $321.8B | |
| P/E as of 2026-08-12 | n/a | 100.10 | |
| PEG as of 2026-08-12 | -0.08 | 4.91 | IBRX lower |
| Net margin as of 2026-08-12 | -598.6% | +4.8% | MRK higher |
| Gross margin as of 2026-08-12 | +99.3% | +77.3% | IBRX higher |
| Operating margin as of 2026-08-12 | -151.9% | +9.6% | MRK higher |
| ROE as of 2026-08-12 | -193.3% | +17.9% | MRK higher |
| ROA as of 2026-08-12 | -172.9% | +7.0% | MRK higher |
| Debt / equity as of 2026-08-12 | 0.00 | 1.07 | IBRX lower |
| Revenue growth (YoY) as of 2026-08-12 | +192.9% | +4.6% | IBRX higher |
| Revenue CAGR (3y) SEC XBRL | +678.6% | +3.1% | IBRX higher |
| Dividend yield as of 2026-08-12 | n/a | +2.6% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-08-12 | 0.07 | 0.20 | |
| 1-year return as of 2026-08-11 close | +207.7% | +63.0% | IBRX higher |
Fundamentals: market data, as of 2026-08-12. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-11.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.